Financiere des Professionnels Fonds d investissement inc. Boosts Stake in BWX Technologies, Inc. $BWXT

Financiere des Professionnels Fonds d investissement inc. grew its stake in shares of BWX Technologies, Inc. (NYSE:BWXT) by 388.9% in the 3rd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 5,070 shares of the technology company’s stock after buying an additional 4,033 shares during the period. Financiere des Professionnels Fonds d investissement inc.’s holdings in BWX Technologies were worth $935,000 at the end of the most recent reporting period.

A number of other institutional investors also recently made changes to their positions in the stock. Invesco Ltd. boosted its stake in shares of BWX Technologies by 139.0% during the second quarter. Invesco Ltd. now owns 1,592,380 shares of the technology company’s stock valued at $229,398,000 after acquiring an additional 926,117 shares during the last quarter. Valeo Financial Advisors LLC lifted its holdings in BWX Technologies by 33,572.0% in the 2nd quarter. Valeo Financial Advisors LLC now owns 1,517,599 shares of the technology company’s stock valued at $2,228,000 after purchasing an additional 1,513,092 shares in the last quarter. William Blair Investment Management LLC boosted its stake in shares of BWX Technologies by 523.2% during the 2nd quarter. William Blair Investment Management LLC now owns 1,517,356 shares of the technology company’s stock worth $218,590,000 after purchasing an additional 1,273,895 shares during the last quarter. Artisan Partners Limited Partnership purchased a new stake in shares of BWX Technologies during the second quarter worth about $183,859,000. Finally, Blair William & Co. IL grew its holdings in shares of BWX Technologies by 28.2% during the second quarter. Blair William & Co. IL now owns 1,003,607 shares of the technology company’s stock worth $144,580,000 after buying an additional 220,616 shares in the last quarter. 94.39% of the stock is owned by institutional investors and hedge funds.

BWX Technologies Price Performance

Shares of BWX Technologies stock opened at $181.91 on Friday. The business’s fifty day moving average price is $183.37 and its 200 day moving average price is $172.07. BWX Technologies, Inc. has a twelve month low of $84.21 and a twelve month high of $218.50. The company has a current ratio of 1.71, a quick ratio of 1.62 and a debt-to-equity ratio of 1.21. The stock has a market capitalization of $16.63 billion, a P/E ratio of 54.63, a PEG ratio of 3.24 and a beta of 0.86.

BWX Technologies (NYSE:BWXT) last announced its quarterly earnings results on Monday, November 3rd. The technology company reported $1.00 EPS for the quarter, topping the consensus estimate of $0.85 by $0.15. The company had revenue of $866.29 million during the quarter, compared to analyst estimates of $795.48 million. BWX Technologies had a return on equity of 30.70% and a net margin of 10.04%.The firm’s revenue was up 28.9% on a year-over-year basis. During the same period in the prior year, the firm posted $0.83 earnings per share. BWX Technologies has set its FY 2025 guidance at 3.750-3.800 EPS. As a group, research analysts anticipate that BWX Technologies, Inc. will post 3.23 earnings per share for the current year.

BWX Technologies Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Wednesday, December 10th. Investors of record on Wednesday, November 19th were issued a $0.25 dividend. The ex-dividend date was Wednesday, November 19th. This represents a $1.00 annualized dividend and a yield of 0.5%. BWX Technologies’s dividend payout ratio (DPR) is presently 30.03%.

Wall Street Analysts Forecast Growth

BWXT has been the topic of several recent analyst reports. Truist Financial upped their price objective on shares of BWX Technologies from $173.00 to $200.00 and gave the company a “hold” rating in a research note on Tuesday, November 4th. Northland Capmk upgraded BWX Technologies to a “strong-buy” rating in a report on Tuesday, September 9th. CJS Securities upgraded BWX Technologies to a “strong-buy” rating in a research note on Friday, December 12th. BTIG Research increased their target price on BWX Technologies from $200.00 to $225.00 and gave the stock a “buy” rating in a research report on Friday, November 7th. Finally, Wedbush restated an “outperform” rating on shares of BWX Technologies in a report on Wednesday, October 1st. Three investment analysts have rated the stock with a Strong Buy rating, six have given a Buy rating and five have issued a Hold rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $196.23.

Insiders Place Their Bets

In other BWX Technologies news, CEO Rex D. Geveden sold 10,000 shares of the business’s stock in a transaction that occurred on Wednesday, November 12th. The shares were sold at an average price of $197.90, for a total transaction of $1,979,000.00. Following the completion of the sale, the chief executive officer directly owned 187,594 shares in the company, valued at $37,124,852.60. The trade was a 5.06% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 0.47% of the stock is currently owned by company insiders.

BWX Technologies Company Profile

BWX Technologies, Inc (NYSE: BWXT) is a specialized supplier of nuclear components and services, primarily serving the U.S. government and commercial markets. The company’s core expertise lies in the design, fabrication and servicing of nuclear propulsion systems for the U.S. Navy, where it supports the maintenance and overhaul of naval nuclear reactors. In addition to defense applications, BWXT develops small modular reactors (SMRs), nuclear fuel and related technologies for non‐defense power generation, offering scalable solutions to meet evolving energy and industrial demands.

Beyond propulsion and power systems, BWXT is a leading producer of medical radioisotopes used in diagnostic imaging and cancer treatment.